BR112017021779A2 - ?uma preparação combinada de anticorpos anti-staphylococcus aureus? - Google Patents

?uma preparação combinada de anticorpos anti-staphylococcus aureus?

Info

Publication number
BR112017021779A2
BR112017021779A2 BR112017021779A BR112017021779A BR112017021779A2 BR 112017021779 A2 BR112017021779 A2 BR 112017021779A2 BR 112017021779 A BR112017021779 A BR 112017021779A BR 112017021779 A BR112017021779 A BR 112017021779A BR 112017021779 A2 BR112017021779 A2 BR 112017021779A2
Authority
BR
Brazil
Prior art keywords
antibody
combined preparation
staphylococcus aureus
binding
protein
Prior art date
Application number
BR112017021779A
Other languages
English (en)
Inventor
Adriana Badarau
Eszter Nagy
Harald Rouha
Lukas Stulik
Zehra Visram
Original Assignee
Arsanis Biosciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arsanis Biosciences Gmbh filed Critical Arsanis Biosciences Gmbh
Publication of BR112017021779A2 publication Critical patent/BR112017021779A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo ?uma preparação combinada de anticorpos anti-staphylococcus aureus?. a presente invenção se refere a uma preparação combinada de anticorpos anti-staphylococcus aureus que compreenda a) um anticorpo de neutralização cruzada de toxinas que compreenda pelo menos um sítio de ligação poliespecífico que se ligue à alfa-toxina (hla) e pelo menos uma das toxinas bicomponentes selecionadas do grupo que consiste de higab, higcb, luksf, luked, luks-hlgb, luksd, higa-lukd, higa-lukf, lukef, luke-hlgb, higc-lukd e higc-lukf; e b) um anticorpo anti-lukgh; e/ou c) um anticorpo opk que reconheça uma proteína de superfície de s. aureus induzindo dessa forma a opk, especificamente um anticorpo de proteína de ligação anti-ig (igbp) que compreenda pelo menos um sítio de ligação à cdr que reconheça quaisquer dos domínios de ligação à igg de s. aureus da proteína a ou sbi.
BR112017021779A 2015-04-17 2016-04-14 ?uma preparação combinada de anticorpos anti-staphylococcus aureus? BR112017021779A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15164000 2015-04-17
PCT/EP2016/058240 WO2016166223A1 (en) 2015-04-17 2016-04-14 Anti-staphylococcus aureus antibody combination preparation

Publications (1)

Publication Number Publication Date
BR112017021779A2 true BR112017021779A2 (pt) 2018-07-10

Family

ID=52997891

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017021779A BR112017021779A2 (pt) 2015-04-17 2016-04-14 ?uma preparação combinada de anticorpos anti-staphylococcus aureus?

Country Status (12)

Country Link
US (1) US20180179267A1 (pt)
EP (1) EP3283514A1 (pt)
JP (1) JP2018513168A (pt)
KR (1) KR20170136637A (pt)
CN (1) CN107873034A (pt)
AU (1) AU2016249837A1 (pt)
BR (1) BR112017021779A2 (pt)
CA (1) CA2978855A1 (pt)
IL (1) IL255062A0 (pt)
MX (1) MX2017012775A (pt)
RU (1) RU2017139800A (pt)
WO (1) WO2016166223A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503232TA (en) 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
WO2015055814A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
BR112017021779A2 (pt) * 2015-04-17 2018-07-10 Arsanis Biosciences Gmbh ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
TWI781130B (zh) 2017-01-03 2022-10-21 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
TW202019956A (zh) 2018-07-24 2020-06-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌凝集因子a(clfa)之抗體
CN113164602A (zh) * 2018-10-09 2021-07-23 免疫医疗有限责任公司 抗金黄色葡萄球菌抗体的组合
AU2019359207A1 (en) 2018-10-09 2021-05-20 Humabs Biomed Sa Antibodies directed against Staphylococcus aureus leukotoxins
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
US20040110226A1 (en) 2002-03-01 2004-06-10 Xencor Antibody optimization
US20180221466A9 (en) * 2006-06-12 2018-08-09 Glaxosmithkline Biologicals S.A. Use of alpha-toxin for treating and preventing staphylococcus infections
EP2617827A1 (en) 2007-03-26 2013-07-24 Celexion, LLC Method for displaying engineered proteins on a cell surface
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2697193C (en) * 2007-09-14 2017-06-06 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
EP2242843B1 (en) * 2007-12-31 2015-05-27 XOMA Technology Ltd. Methods and materials for targeted mutagenesis
CN105734678B (zh) 2010-07-16 2019-11-05 阿迪马布有限责任公司 合成多核苷酸文库
DK3403669T3 (da) * 2011-06-19 2020-08-24 Univ New York Fremgangsmåder til behandling og forebyggelse af staphylococcus aureus-infektioner og forbundne tilstande
ES2609817T3 (es) * 2011-06-19 2017-04-24 New York University Leucotoxina E/D como nuevo agente antiinflamatorio y microbicida
JP6317670B2 (ja) * 2011-08-15 2018-04-25 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌プロテインａに対する抗体に関連した組成物および方法
JP6228186B2 (ja) * 2012-04-17 2017-11-08 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗体
SG11201503232TA (en) * 2012-11-06 2015-05-28 Medimmune Llc Antibodies to s. aureus surface determinants
US20160074497A1 (en) 2013-05-03 2016-03-17 The University Of Chicago Staphylococcus live cell vaccines
WO2014187746A2 (en) * 2013-05-21 2014-11-27 Arsanis Biosciences Gmbh Generation of highly potent antibodies neutralizing the lukgh (lukab) toxin of staphylococcus aureus
WO2015055814A1 (en) * 2013-10-17 2015-04-23 Arsanis Biosciences Gmbh Cross-reactive staphylococcus aureus antibody sequences
KR20160098358A (ko) * 2013-12-19 2016-08-18 알사니스 바이오사이언시스 게엠베하 스타필로코커스 아우레우스의 LukGH (LukAB) 독소에 대해 지시된 항체 및 항체 서열
EP3180620B1 (en) * 2014-08-12 2020-01-01 X4 Pharmaceuticals (Austria) GmbH Predicting s. aureus disease
BR112017021779A2 (pt) * 2015-04-17 2018-07-10 Arsanis Biosciences Gmbh ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
KR20170137111A (ko) * 2015-04-17 2017-12-12 알사니스 바이오사이언시스 게엠베하 에스. 아우레우스의 면역글로불린 결합 단백질에 대해 지시된 항체

Also Published As

Publication number Publication date
IL255062A0 (en) 2017-12-31
CN107873034A (zh) 2018-04-03
RU2017139800A (ru) 2019-05-17
US20180179267A1 (en) 2018-06-28
WO2016166223A1 (en) 2016-10-20
AU2016249837A1 (en) 2017-09-28
KR20170136637A (ko) 2017-12-11
CA2978855A1 (en) 2016-10-20
JP2018513168A (ja) 2018-05-24
EP3283514A1 (en) 2018-02-21
MX2017012775A (es) 2019-04-29

Similar Documents

Publication Publication Date Title
BR112017021779A2 (pt) ?uma preparação combinada de anticorpos anti-staphylococcus aureus?
MA54513A (fr) Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs
AU2018318303A1 (en) Antigen-binding proteins targeting shared antigens
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
MA54514A (fr) Anticorps se liant à cd3
BR112017028353A2 (pt) anticorpos para cd40 com atividade agonista melhorada
MA40913A (fr) Conjugués anticorps-médicament
EA201892362A1 (ru) Агонистические антитела, которые связываются с cd40 человека, и варианты их применения
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
WO2017136820A3 (en) Fabs-in-tandem immunoglobulin and uses thereof
CU24498B1 (es) Anticuerpos de factor xi
BR112017025080A2 (pt) composto conjugado de fármaco com anticorpo anti-cd123, composição conjugada de fármaco com anticorpo, método de tratamento de um paciente que tem um câncer que expressa cd123, composição farmacêutica, e, anticorpo intacto ou fragmento de ligação de antígeno
BR112017027254A2 (pt) anticorpos anti-cd123 e conjugados e derivados dos mesmos
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EA201790961A1 (ru) Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения
BR112016028043A2 (pt) composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
BR112016014731A2 (pt) Anticorpos anti-baff
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112016001782A2 (pt) Proteína de fusão terapêutica
BR112016014163A2 (pt) anticorpos direcionados contra a toxina lukgh (lukab) de staphylococcus aureus e as sequências de anticorpos, seu uso no tratamento ou no diagnóstico de infecção por s. aureus, as preparações farmacêuticas e para diagnóstico, os ácidos nucleicos que codificam os anticorpos, o paratopo isolado dos anticorpos e o epítopo conformacional isolado
BR112018072211A2 (pt) anticorpos anti tl1a e utilizações dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]